Clinical Trials (PDQ®) - National Cancer Institute

Page Options

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp online chat

	NCI Highlights


	Maintenance Rituximab for Follicular Lymphoma Azacitidine Improves Survival in MDS Second Stem Cell Transplant Not Helpful in Myeloma

Pilot Phase II Study with Anguidine to Prevent Myelosuppression in Patients with Leukemia and Solid Tumors Treated with ARA-C

Basic Trial Information
Objectives
Entry Criteria
Expected Enrollment
Outline
Trial Contact Information

Basic Trial Information

Phase Type Status Age Sponsor Protocol IDs
Phase II Treatment Closed no age specified MDA-DT-7977P

Objectives

I.  Determine whether prior and concurrent treatment with low doses of 
anguidine can ameliorate or prevent myelosuppression in patients with leukemia 
and solid tumors treated with cytosine arabinoside.
II.  Determine the qualitative and quantitative toxicities associated with 
treatment with both of these agents.

Entry Criteria

Disease Characteristics:

See General Eligibility Criteria

Patient Characteristics:

See General Eligibility Criteria

General Eligibility Criteria:

Patients with leukemia and solid 
tumors who might derive benefit from treatment with cytosine arabinoside.

Expected Enrollment

Protocol closed February 1983.

Outline

Nonrandomized study.
Single-agent Chemotherapy plus Myeloprotective Therapy.  Cytosine arabinoside, 
ARA-C, NSC-63878; plus Anguidine, ANG, NSC-141537.

Trial Contact Information

Trial Lead Organizations

M. D. Anderson Cancer Center at University of Texas

Eugene M. McKelvey, MD, Protocol chair
Ph: 713-792-2570; 800-392-1611

Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol.